CheckMate 8HW: HRQoL outcomes of nivolumab and ipilimumab in MSI-H/dMMR mCRC

Chiara Cremolini, MD, PhD, University of Pisa, Pisa, Italy, discusses the health-related quality of life (HRQoL) outcomes from the CheckMate 8HW study (NCT04008030), which compared first-line nivolumab with ipilimumab to chemotherapy in MSI-H/dMMR metastatic colorectal cancer (mCRC). HRQoL significantly improved in the checkpoint inhibitor group, where patients reported better Global Health Status, fewer symptoms, and a reduced risk of HRQoL deterioration. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.